Search
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.
Magnesium salicylate
go.drugbank.com/drugs/DB01397ApprovedIt is available in several over-the-counter (OTC) formulations.
Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIn 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … practice, central nervous system stimulative effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by the FDA
Desmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalOn January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery
Products: Nu-desmopressin SprayEstradiol valerate
go.drugbank.com/drugs/DB13956ApprovedInvestigationalVet approvedThus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women [FDA Label]. … As a pro-drug of estradiol, estradiol acetate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located in
Decitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedMacimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved
Chlorothiazide
go.drugbank.com/drugs/DB00880ApprovedInvestigationalVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p812)